
    
      This is a 2-part dose escalation and dose expansion study. Dose escalation uses a modified
      "3+3" design and continues until a maximum tolerated dose (MTD) or recommended phase 2 dose
      (RP2D) is identified. In part 2, subjects with selected tumor types will be enrolled at the
      MTD or RP2D.
    
  